<DOC>
	<DOCNO>NCT01754714</DOCNO>
	<brief_summary>Investigation Effects Different Doses SAMe Subjects Nonalcoholic Fatty Liver Disease non-treated match healthy volunteer control group</brief_summary>
	<brief_title>Study Investigate Effects Different Doses S-adenosyl-L-methionine ( SAMe ) Subjects With Nonalcoholic Fatty Liver Disease Non-treated Matched Healthy Volunteers Control Group</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Inclusion Criteria Subjects nonalcoholic steatohepatitis base histology medical history within last 3 year Subjects stable metabolic condition since histology NASH ( Nonalcoholic Steatohepatitis ) Exclusion Criteria Subjects extrahepatic biliary obstruction Subjects primary sclerosing cholangitis ( PSC ) Subjects primary biliary cirrhosis ( PBC ) Any form malignancy within past 5 year and/or basal cell carcinoma squamous cell carcinoma skin within past two year History active substance abuse ( oral , inhaled inject ) within one year prior study Subjects renal impairment ( creatinine level &gt; 2.0 mg/dL ) Subjects know hypersensitivity active substance ( ademetionine ) methionine inactive ingredient Subjects know genetic defect affect methionine cycle and/or cause homocystinuria and/or hyperhomocysteinemia ( e.g. , cystathionine betasynthase deficiency , Vitamin B12 metabolism defect ) Subjects total parenteral nutrition year prior screen Subjects plan bariatric surgery ( jejunoileal bypass gastric weight loss surgery ) Extrahepatic cholestasis ( proven ultrasound ) Subjects alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 5 upper limit normal ( ULN ) Subject serum total bilirubin ( STB ) &gt; 5 ULN Subjects liver transplantation subject wait list liver transplantation Subjects follow disease medical history : Viral hepatitis ( serum positive HBcAb ( hepatitis B core antibody ) Hepatitis C Virus ( HCV ) ribonucleic acid ( RNA ) Evidence autoimmune liver disease Wilson 's disease Hemochromatosis Alpha1antitrypsin deficiency Known positivity antibody human immunodeficiency virus ( HIV ) Known heart failure New York heart Association class 3 4 Current history significant alcohol consumption period three consecutive month within five year prior screen ( significant alcohol consumption define &gt; 3 U ( unit ) /day men &gt; 2 U/day woman , average ) binge drink inability reliably quantify alcohol consumption . Clinical histological evidence cirrhosis F4 Subjects history biliary diversion Subjects uncontrolled diabetes mellitus define HbA1c ( hemoglobin A1c ) &gt; 8.0 % screen Concomitant medication B12 , folate , betaine choline Concomitant treatment glitazone within past year prior study Subjects know folate B12 deficiency BMI ( body mass index ) &gt; 40 kg/m2 History major depression diagnostic statistical manual mental disorder ( DSMIV ) bipolar disease Women childbearing potential : positive urine pregnancy test screen unwillingness use effective form birth control study . Breastfeeding woman Any condition , opinion investigator , justify patient 's inclusion study Investigational drug intake within one month prior study Active , serious medical disease likely lifeexpectancy less five year Uncooperative attitude reasonable likelihood noncompliance protocol reason , investigator 's opinion , prohibit inclusion subject study Legal incapacity limit legal capacity , incarcerate . Inability return schedule visit . Inability understand follow requirement protocol local language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Steatohepatitis</keyword>
</DOC>